CNSP
Cns Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$4.51
-0.04 (-0.88%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 401.0K | 379.4K | 323.5K |
| Net Income | 137.9K | 129.6K | 106.9K |
| EPS | — | — | — |
| Profit Margin | 34.4% | 34.2% | 33.1% |
| Rev Growth | +21.3% | -7.8% | +5.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 306.2K | 352.4K | 387.0K |
| Total Equity | 1.29M | 1.09M | 1.24M |
| D/E Ratio | 0.24 | 0.32 | 0.31 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 186.8K | 161.4K | 136.4K |
| Free Cash Flow | 134.0K | 130.1K | 98.1K |